ÐÂÎÅ×ÊѶ
æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡Z6ÈËÉú¾ÍÊDz©¶àëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ
ÈÕÆÚ£º
2026Äê04ÔÂ02ÈÕ 14:40
ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ½¡¿µÌôÕ½µÄµ±Ï £¬Z6ÈËÉú¾ÍÊDz©£¨ÒÔϼò³Æ“Z6ÈËÉú¾ÍÊDz©”£©´«À´Õñ·ÜÈËÐĵÄÏûÏ¢£¡Æä×ÔÖ÷Ñз¢µÄ´´ÐÂС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£© £¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£Ð͵ÄÁÙ´²Ç°Ñо¿ÖÐ £¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØЧ¹û£»½áºÏÆä¶Ô¼¡ÈâµÄ±£³Ö×÷Óà £¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷½Ú×÷Óà £¬ÓÐÍû´øÀ´²îÒ컯µÄÁÙ´²Ñ¡Ôñ¡£
Ò»¡¢¾ªÑ޵ļõÖØÊý¾Ý
DB/DBСÊóÊÇÑо¿·ÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾µä¶¯ÎïÄ£ÐÍ £¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ÄÜȱÏÝ £¬±íÏÖ³öÑÏÖصķÊÅÖ¡¢¸ßѪÌǺʹúлÎÉÂÒµÈÖ¢×´¡£ÔÚZ6ÈËÉú¾ÍÊDz©¿ªÕ¹µÄÕâÏîÁÙ´²Ç°Ñо¿ÖÐ £¬¹«Ë¾×ÔÑеÄС·Ö×Ó»·ëÄÕ¹ÏÖ³öÓÅÒìµÄ¼õÖØЧ¹û¡£
ÊÔÑé½á¹ûÏÔʾ £¬¾¹ýΪÆÚ8ÖܵÄÖÎÁÆ £¬Óë¿Õ°×¶ÔÕÕ×éDB/DBСÊóÏà±È £¬MCR»·ëĽϸ߼ÁÁ¿×éµÄСÊóµÄÌåÖØϽµ·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶ £¬Ê¹DB/DBСÊóµÄÌåÖØÔö³¤Ç÷ÊÆÃ÷ÏÔ·Å»º £¬½Ó½ü½¡¿µ¶ÔÕÕ×éˮƽ¡£
¶þ¡¢¶àÏî´úлָ±êÈ«Ãæ¸ÄÉÆ
MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉƸÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ãæ £¬Í¬Ñù±íÏÖÓÅÒ죺
1.TGˮƽ£ºÏÔÖø½µµÍDB/DBСÊóµÄTGˮƽ £¬ÓÅÓÚGLP-1¶àëÄ×飻
2.HDL-Cˮƽ£ºÃ÷ÏÔÉý¸ß £¬ÓÅÓÚGLP-1¶àëÄ×飻ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯·çÏÕ£»
3.ѪÌÇˮƽ£ºÖÎÁÆ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é½Ó½ü£»
4.ÄòÌÇˮƽ£ºÖÎÁÆ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë£»
5.ÌÇ»¯Ñªºìµ°°×£¨HbA1c£©£ºÓëÄ£ÐÍ×éÏà±È £¬HbA1cϽµ·ù¶È´ïÔ¼1/3¡£
|ÁªºÏDZÁ¦
ÖµµÃÒ»ÌáµÄÊÇ £¬Z6ÈËÉú¾ÍÊDz©ÒÑ¿ªÕ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©ÁªºÏʹÓõÄÑо¿ £¬½á¹ûÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖСÊóÄ£ÐÍÖÐ £¬Á½ÕßÔÚ¼õÖØЧ¹û¼°¼¡Èâ±£»¤·½Ãæ¾ßÓÐÃ÷È·µÄÐͬЧӦ£º
1.Ðͬ¼õÖØ£ºÁªºÏÓÃÒ©×é±íÏÖ³ö¸üÏÔÖøµÄ¼õÖØЧ¹û £¬ÓÅÓÚµ¥Ò©ÖÎÁÆ£»
2.¼õÉÙ¼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐЧ»º½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌâ £¬Ìá¸ßÕûÌåÖÎÁÆ°²È«ÐÔ¡£
Èý¡¢¶à°ÐµãÐͬ×÷Ó㺻·ëĵĴ´Ð»úÖÆ
MCR»·ëÄÖ®ËùÒÔÄܹ»ÔÚ¼õÖؼ°ÆäËû´úлָ±êÉÏÈ¡µÃÈç´ËÓÅÒìµÄ³É¼¨ £¬ÓëÆä¶ÀÌصÄ×÷ÓûúÖÆÃܲ»¿É·Ö¡£×÷ΪһÖÖС·Ö×Ó»·ëÄÒ©Îï £¬Äܹ»Í¬Ê±¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸ö¹Ø¼ü°Ðµã £¬Í¨¹ý¶à°ÐµãÐͬ×÷Óà £¬·¢»ÓÆä׿ԽµÄ´úлµ÷½Ú¹¦Ð§¡£
|¼¤»îMC4R£ºÒÖÖÆʳÓû £¬´Ù½øÖ¬·¾·Ö½â
MC4RÊÇÖÐÊàÉñ¾ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄ¹Ø¼üÊÜÌå¡£Z6ÈËÉú¾ÍÊDz©MCR»·ëÄ×÷ΪMC4R¼¤¶¯¼Á £¬Äܹ»´Ù½øÖ¬·¾·Ö½â £¬ÒÖÖÆÖ¬·¾Éú³É£»´Ù½ø°×É«Ö¬·¾×éÖ¯ºÖ±ä£»Ìá¸ßÒȵºËØÃô¸ÐÐÔ£»ÔÚ²»ÏÔÖøÒÖÖÆʳÓûµÄÇ°ÌáÏÂʵÏÖ¼õÖ¬ £¬±ÜÃâÑáʳ¸±×÷ÓÃ1¡£
|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷½Ú £¬»Ö¸´ÊÝËØÃô¸ÐÐÔ
MC1RÖ÷Òª²ÎÓëÃâÒßµ÷½ÚºÍÑ×Ö¢·´Ó¦¡£Í¨¹ý¼¤»îMC1R £¬Äܹ»ÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢»·¾³ £¬½µµÍÑ×Ö¢Òò×Ó£¨°üÀ¨IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í´ï´Ó¶ø»Ö¸´ÊÝËØÃô¸ÐÐԺ͵÷½ÚÃâÒß·´Ó¦ £¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡¾ßÓÐDZÔÚÖÎÁƼÛÖµ2¡£
ËÄ¡¢¹ãÀ«µÄÓ¦ÓÃÇ°¾°£º´úлÎÉÂÒÓë×ÔÉíÃâÒßÊÊÓ¦Ö¢
»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°Ñо¿ÖÐÕ¹ÏÖ³öµÄ׿Խ¼õÖØЧ¹ûºÍ¶àϵͳ´úл¸ÄÉÆ×÷Óà £¬Z6ÈËÉú¾ÍÊDz©¶ÔÆäδÀ´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÓ¦ÓÃÇ°¾°³äÂúÐÅÐÄ¡£
´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ãæ £¬MCR»·ëIJ»½öÄܼõÖØ £¬»¹ÄÜͬ²½¸ÄÉÆѪÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê £¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏî¾ßÓиÉԤDZÁ¦¡£
×ÔÉíÃâÒßÓëÑ×Ö¢Ïà¹Ø¼²²¡·½Ãæ £¬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷½Ú×÷Óà £¬Î´À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐԹؽÚÑ×£»ÂýÐÔÉö²¡£¨CKD£©£»ÌÇÄò²¡Éö²¡£¨DN£©µÈÊÊÓ¦Ö¢¡£
½ÓÏÂÀ´ £¬¹«Ë¾½«¼ÌÐøÍƶ¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾ÀíѧÑо¿ £¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î £¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ £¬¿ìËÙ½«²îÒ컯µÄºÃÒ©´ø¸øÓµÓÐÏà¹ØÖÎÁÆÐèÇóµÄ»¼ÕßȺÌå¡£
ÎÄÕÂÀ´Ô´ÓÚҩʱ´ú¹«ÖÚºÅ
²Î¿¼ÎÄÏ×
1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x
2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ